核因子白细胞介素3调节因子促进乳腺癌细胞增殖和侵袭能力研究

目的探讨核因子白细胞介素3调节因子(NFIL3)对人乳腺癌细胞增殖和侵袭能力的影响AZD1080。方法采用慢病毒载体构建过表达及敲减NFIL3乳腺癌细胞系BT549和Hs578T(中国科学院上海细胞库), 以荧光定量聚合酶链反应(PCR)及蛋白印迹实验(Western blot)进行验证。通过细胞计数试剂盒(MTT)检测细胞增殖、小室细胞迁移实验(Transwell)和侵袭实验以及动物模型裸鼠皮下荷瘤和鼠尾静脉肺转移实验, 验证NFIL3对乳腺癌细胞增殖和侵袭能力。组间比较采用t检验及One-way ANOVA检验。结果 MTT细胞增殖实验证实, 过表达NFIL3组与对照组相比促进细胞增殖(BT549-对照4.37±0.27比BT549-NFIL3 5.98±0.31, t=6.783, P0.01;Hs578T-对照4.75±0.32比Hs578T-NFIL3 6.05±0.39, t=4.463, P0.05), 敲减NFIL3抑制细胞增殖(BT549-PLKO 4.17±0.20比BT549-sh1 2.83±0.29, t=6.557, P0.01;BT549-PLKO 4.17±0.20比BT549-sh2 3.11±0.17, t=4.943, P0.01;Hs578T-PLKO 4.11±0.31比Hs578T-sh1 3.11±0.21, t=12.540, P0.01;Hs578T-PLKO 4.11±0.31比Hs578T-sh2 3.01±0.23, t=10.930, P0.01);Transwell细胞迁移证实, 过表达NFIL3组与对照组比较促进细胞迁移[BT549-对照(198.00±28.03)个比BT549-NFIL3 (397.00±52.10)个, t=10.640, P0.01;Hs578T-对照(294.00±32.01)个比Hs578T-NFIL3 (598.00±46.11)个, t=17.130, P0.01], 敲减NFIL3抑制细胞迁移[BT549-PLKO (178GDC-0941生产商.00±23.11)个比BT549-sh1 (41.01±15.12)个, t=9.820, P0.01;BT549-PLKO (178.00±23.11)个比BT549-sh2 (56.10±24.27)个, t=10.430, P0.01;Hs578T-PLKO (197.60±21.13)个比Hs578T-sh1 (69.80±19.96)个, t=8.403, P0.01;Hs578T-PLKO (197.60±21.13)个比Hs578T-sh2 (58.00±14.26)个, t=8.042, P0.01];Transwell细胞侵袭证实, 过表达NFIL3组与对照组比较促进细胞侵袭[BT549-对照(74.6±23.14)个比BT549-NFIL3 (142.50±28.30)个, t=5.874, P0.0寻找更多1;Hs578T-对照(103.20±28.14)个比Hs578T-NFIL3 (183.70±22.14)个, t=7.110, P0.01], 敲减NFIL3抑制细胞侵袭[BT549-PLKO (89.13±19.86)个比BT549-sh1 (37.45±15.63)个, t=9.062, P0.01;BT549-PLKO (89.13±19.86)个比BT549-sh2 (50.17±17.12)个, t=8.067, P0.01;Hs578T-PLKO (135.10±16.52)个比Hs578T-sh1 (47.10±16.30)个, t=6.747, P0.01;Hs578T-PLKO (135.10±16.52)个比Hs578T-sh2 (58.45±14.13)个, t=6.598, P0.01]。过表达NFIL3组与对照组比较促进裸鼠皮下肿瘤生长[Hs578T-对照(0.126±0.017) g比Hs578T-NFIL3 (0.301±0.098) g, t=3.934, P0.01], 敲减NFIL3组抑制裸鼠皮下肿瘤生长[Hs578T-PLKO (0.190±0.078) g比Hs578T-sh (0.040±0.019) g, t=4.168, P0.01];过表达NFIL3组与对照组比较, 增加鼠尾静脉肺转移瘤形成数量[Hs578T-对照(1.45±0.98)个比Hs578T-NFIL3(4.12±1.79)个, t=4.137, P0.01], 敲减NFIL3组减少鼠尾静脉肺转移瘤形成数量[Hs578T-PLKO(1.53±1.21)个比Hs578T-sh(0.34±0.27)个, t=3.035, P0.05]。结论 NFIL3在乳腺癌细胞系中具有促进癌细胞增殖、迁移和侵袭的能力。

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>